Presented by
Naomi Zak
Nominated by
Weizmann Institute of Science
BiomX is a microbiome drug discovery company developing customised phage therapies that seek and destroy harmful bacteria linked to chronic diseases, such as inflammatory bowel disease (IBD) and cancer. The microbiome refers to the bacteria residing in and on the human body. Microbiome research constitutes a new and fast-developing field, and it offers a novel approach to address various diseases. Research has found growing evidence for the presence of harmful bacteria in the microbiome in chronic diseases such as cancer and IBD. In these cases, antibiotics are not a viable solution because they increase antimicrobial resistance and disrupt the microbiome. Bacteriophages (bacterial viruses), however, offer a selective and targeted means to eradicate specific bacterial strains. BiomX uses novel computational and synthetic biology to discover and validate proprietary bacterial targets and to customise their natural and engineered phage compositions to attack these targets. BiomX’s innovative therapies thus address the unmet needs of millions of patients worldwide suffering from cancer, IBD, and other chronic diseases.